Biological and genetic determinants of serum apoC-III concentration: Reference limits from the Stanislas Cohort

Journal of Lipid Research

Volumn 44, Issue 2, 2003, Pages 430-436

  Tilly, Peggy ^a   Sass, Catherine ^a   Vincent Viry, Monique ^a   Aguillon, Dominique ^a   Siest, Gérard ^a   Visvikis, Sophie ^a  

^a Centre de Medecine Preventive   (France)

Author keywords

Apolipoproteins; Lipids; Polymorphism; Reference values

Indexed keywords

APOLIPOPROTEIN C3;

ALLELE; ARTICLE; BLOOD SAMPLING; CELL VIABILITY; COHORT ANALYSIS; GENE LOCATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REFERENCE VALUE; TURBIDIMETRY;

ADOLESCENT; ADULT; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; REFERENCE VALUES;

EID: 0037516607     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M200006-JLR200     Document Type: Article

References (40)

1. Shachter, N. S. 2001. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr. Opin. Lipidol. 12: 297-304.
2. Ito, Y., N. Azrolan, A. O'Connell, A. Walsh, and J. L. Breslow. 1990. Hypertriglyceridemia as a result of human apo C-III gene expression in transgenic mice. Science. 249: 790-793.
3. Jong, M. C., and L. M. Havekes. 2000. Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice. Int. J. Tissue React. 22: 59-66.
4. Krauss, R. M. 1998. Atherogenicity of triglyceride-rich lipoproteins. Am. J. Cardiol. 81: 13B-17B.
5. Sacks, F. M., P. Alaupovic, L. A. Moye, T. G. Cole, B. Sussex, M. J. Stampfer, M. A. Pfeffer, and E. Braunwald. 2000. VLDL, Apolipoproteins B, C-III, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial. Circulation. 102: 1886-1892.
6. Alaupovic, P. 1996. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods Enzymol. 263: 32-60.
7. Attia, N., V. Durlach, M. Cambilleau, D. Roche, and A. Girard Globa. 2000. Postprandial concentrations and distribution of apo C-III in type 2 diabetic patients. Effect of bezafibrate treatment. Atherosclerosis. 149: 427-433.
8. Davit-Spraul, A., M. L. Pourci, V. Atger, M. Cambillau, M. Hadchouel, N. Moatti, and A. Legrand. 1996. Abnormal lipoprotein pattern in patients with Alagille syndrome depends on Icterus severity. Gastroenterology. 111: 1023-1032.
9. Moberly, J. B., P. O. Attman, O. Samuelsson, A. C. Johansson, C. Knight-Gibson, and P. Alaupovic. 1999. Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia. Miner. Electrolyte Metab. 25: 258-262.
10. Tada, H., Y. Irie, A. Yagoro, H. Ohya, S. Hayashi, R. Fushimi, H. Tamaki, and N. Amino. 1994. Serum concentrations of apolipoproteins in patients with thyroid dysfunction. Thyroidology. 6: 93-97.
11. Rifai, N., and L. M. Silverman. 1986. Immunoturbidimetric techniques for quantifying apolipoproteins CII and C-III. Clin. Chem. 32: 1969-1972.
12. Noma, A., Y. Hata, and Y. Goto. 1991. Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values, and age- and sex-related differences. Clin. Chim. Acta. 199: 147-157.
13. Dallongeville, J., A. Meirhaeghe, D. Cottel, J. C. Fruchart, P. Amouyel, and N. Helbecque. 2000. Gender related association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France. Atherosclerosis. 150: 149-157.
14. Peacock, R. E., A. Temple, V. Gudnason, M. Rosseneu, and S. E. Humphries. 1997. Variation at the lipoprotein lipase and apolipoprotein AI-C-III gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland: interaction between genotype, gender, and smoking status. Genet. Epidemiol. 14: 265-282.
15. Dallinga-Thie, G. M., T. M. Linde-Sibenius, J. I. Rotter, R. M. Cantor, X. Bu, A. J. Lusis, and T. W. de Bruin. 1997. Complex genetic contribution of the Apo AI-C-III-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes. J. Clin. Invest. 99: 953-961.
16. Groenendijk, M., R. M. Cantor, N. H. Blom, J. I. Rotter, T. W. de Bruin, and G. M. Dallinga-Thie. 1999. Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia. J. Lipid Res. 40: 1036-1044.
17. Weinstock, P. H., C. L. Bisgaier, K. Aalto-Setala, H. Radner, R. Ramakrishnan, S. Levak-Frank, A. D. Essenburg, R. Zechner, and J. L. Breslow. 1995. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J. Clin. Invest. 96: 2555-2568.
18. Zhao, S. P., M. H. Verhoeven, J. Vink, L. Hollaar, L. A. van Der, P. de Knijff, and E M. 't Hooft. 1993. Relationship between apolipoprotein E and low density lipoprotein particle size. Atherosclerosis. 102: 147-154.
19. Wittrup, H. H., A. Tybjaerg-Hansen, and B. G. Nordestgaard. 1999. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation. 99: 2901-2907.
20. Siest, G., A. Schlenck, M. Starck, M. Vincent-Viry, F. Schiele, and S. Visvikis. 2000. Apolipoprotein E: Laboratory determinations and clinical significance. In Handbook of lipoprotein testing. N. Rifai, G. R. Warnick, and M. H. Dominiczak, editors. AACC, Washington, DC. 401-440.
21. Groenendijk, M., R. M. Cantor, T. W. de Bruin, and G. M. Dallinga-Thie. 2001. The apoAI-C-III-AIV gene cluster. Atherosclerosis. 157: 1-11.
22. Fisher, R. M., H. Burke, V. Nicaud, C. Ehnholm, and S. E. Humphries. 1999. Effect of variation in the apo A-IV gene on body mass index and fasting and postprandial lipids in the European Atherosclerosis Research Study II. J. Lipid Res. 40: 287-294.
23. Siest, G., S. Visvikis, B. Herbeth, R. Gueguen, M. Vincent-Viry, C. Sass, B. Beaud, E. Lecomte, J. Steinmetz, J. Locuty, and P. Chevrier. 1998. Objectives, design and recruitment of a familial and longitudinal cohort for studying gene-environment interactions in the field of cardiovascular risk: the Stanislas cohort. Clin. Chem. Lab. Med. 36: 35-42.
24. Marshall, W. A., and J. M. Tanner. 1969. Variations in pattern of pubertal changes in girls. Arch. Dis. Child. 44: 291-303.
25. Marshall, W. A., and J. M. Tanner. 1970. Variations in the pattern of pubertal changes in boys. Arch. Dis. Child. 45: 13-23.
26. Miller, S. A., D. D. Dykes, and H. E Polesky. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215.
27. Cheng, S., M. A. Grow, C. Pallaud, W. Klitz, H. A. Erlich, S. Visvikis, J. J. Chen, C. R. Pullinger, M. J. Malloy, G. Siest, and J. P. Kane. 1999. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res. 9: 936-949.
28. Bohnet, K., A. Regis-Bailly, M. Vincent-Viry, A. Schlenck, R. Gueguen, G. Siest, and S. Visvikis. 1996. Apolipoprotein E genotype epsilon 4/epsilon 2 in the STANISILAS Cohort Study-dominance of the epsilon 2 allele? Ann. Hum. Genet. 60: 509-516.
29. Siest, G., J. Henny, and F. Schiele. 1990. Références en biologie clinique. Elsevier, Paris, Collection BIO.
30. Contois, J. H., J. R. McNamara, C. J. Lammi-Keefe, P. W. Wilson, T. Massov, and E. J. Schaefer. 1996. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin. Chem. 42: 515-523.
31. Contois, J., J. R. McNamara, C. Lammi-Keefe, P. W. Wilson, T. Massov, and E. J. Schaefer. 1996. Reference intervals for plasma apolipoprotein A-1 determined with a standardized commercial immuno-turbidimetric assay: results from the Framingham Offspring Study. Clin. Chem. 42: 507-514.
32. Vincent-Viry, M., F. Schiele, R. Gueguen, K. Bohnet, S. Visvikis, and G. Siest. 1998. Biological variations and genetic reference values for apolipoprotein E serum concentrations: results from the STANISLAS cohort study. Clin. Chem. 44: 957-965.
33. Bertrais, S., B. Balkau, M. A. Charles, S. Vol, C. Calvet, J. Tichet, and E. Eschwege. 2000. Puberty-associated differences in total cholesterol and triglyceride levels according to sex in French children aged 10-13 years. Ann. Epidemiol. 10: 316-323.
34. Lecomte, E., B. Herbeth, E Paille, J. Steinmetz, Y. Arthur, and G. Siest. 1996. Changes in serum apolipoprotein and lipoprotein profile induced by chronic alcohol consumption and withdrawal: determinant effect on heart disease? Clin. Chem. 42: 1666-1675.
35. Pallaud, C., R. Gueguen, C. Sass, M. Grow, S. Cheng, G. Siest, and S. Visvikis. 2001. Genetic influences on lipid metabolism trait variability within the Stanislas Cohort. J. Lipid Res. 42: 1879-1890.
36. Shoulders, C. C., T. T. Grantham, J. D. North, A. Gaspardone, F. Tomai, A. de Fazio, F. Versaci, P. A. Gioffre, and N. J. Cox. 1996. Hypertriglyceridemia and the apolipoprotein C-III gene locus: lack of association with the variant insulin response element in Italian school children. Hum. Genet. 98: 557-566.
37. Shoulders, C. C., P. J. Harry, L. Lagrost, S. E. White, N. F. Shah, J. D. North, M. Gilligan, P. Gambert, and M. J. Ball. 1991. Variation at the apo AI/C-III/AIV gene complex is associated with elevated plasma levels of apo C-III. Atherosclerosis. 87: 239-247.
38. Waterworth, D. M., P. J. Talmud, S. R. Bujac, R. M. Fisher, G. J. Miller, and S. E. Humphries. 2000. Contribution of apolipoprotein C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men. Arterioscler Thromb. Vasc. Biol. 20: 2663-2669.
39. Russo, G. T., J. B. Meigs, L. A. Cupples, S. Demissie, J. D. Otvos, P. W. Wilson, C. Lahoz, D. Cucinotta, P. Couture, T. Mallory, E. J. Schaefer, and J. M. Ordovas. 2001. Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary, heart disease risk: the Framingham offspring study. Atherosclerosis. 158: 173-181.
40. Vergnes, L., T. Taniguchi, K. Omori, M. M. Zakin, and A. Ochoa. 1997. The apolipoprotein A-I/C-III/A-IV gene cluster: ApoC-III and ApoA-IV expression is regulated by two common enhancers. Biochim. Biophys. Acta. 1348: 299-310.